Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

The need for increased utilization of statins after occlusive stroke.

Hebert PR, Evans D, Schneider WR, Rodriquez-Paz E, Hennekens CH.

J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):364-7. doi: 10.1177/1074248410390368. Epub 2010 Dec 30. Review.

PMID:
21193682
2.

The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.

Hennekens CH, Schneider WR.

Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107. Review.

PMID:
18095910
3.

Statins and stroke prevention.

Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J.

Cerebrovasc Dis. 2007;24(2-3):170-82. Epub 2007 Jun 27. Review.

PMID:
17596685
4.
5.

Atorvastatin: its clinical role in cerebrovascular prevention.

Gaspardone A, Arca M.

Drugs. 2007;67 Suppl 1:55-62. Review.

PMID:
17910521
6.

Effect of statins in stroke prevention.

Amarenco P.

Curr Opin Lipidol. 2005 Dec;16(6):614-8. Review.

PMID:
16276237
7.

Atorvastatin in prevention of stroke and transient ischaemic attack.

Amarenco P.

Expert Opin Pharmacother. 2007 Nov;8(16):2789-97. Review.

PMID:
17956199
8.

Statins for the prevention of first or recurrent stroke.

Athyros VG, Kakafika AI, Tziomalos K, Papageorgiou AA, Karagiannis A.

Curr Vasc Pharmacol. 2008 Apr;6(2):124-33. Review.

PMID:
18393914
9.
11.

Statin therapy and stroke prevention: what was known, what is new and what is next?

Mazighi M, Lavallée PC, Labreuche J, Amarenco P.

Curr Opin Lipidol. 2007 Dec;18(6):622-5. Review.

PMID:
17993806
12.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

13.

Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.

Pedersen TR.

Am J Cardiovasc Drugs. 2010;10 Suppl 1:10-7. doi: 10.2165/1158822-S0-000000000-00000. Review.

PMID:
21391729
15.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

PMID:
16973506
16.

Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).

LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators.

Am J Cardiol. 2007 Sep 1;100(5):747-52. Epub 2007 Jun 14.

PMID:
17719314
17.

Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety.

Kulik A, Ruel M.

Expert Opin Drug Saf. 2009 Sep;8(5):559-71. doi: 10.1517/14740330903188413. Review.

PMID:
19673591
18.
19.

High-dose atorvastatin after stroke or transient ischemic attack.

Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.

N Engl J Med. 2006 Aug 10;355(6):549-59.

20.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326

Supplemental Content

Support Center